source
- FDA grants rapid approval to Revolution Medicines' pancreatic cancer drug RasonqueFDA approved Revolution Medicines' pancreatic cancer therapy Rasonque, just over a month after submission using a priority review voucher. The drug, formerly known as daraxonrasib, is for patients…
- FDA approves Rasonque, first therapy targeting genetic cause of advanced pancreatic cancerThe U.S. Food and Drug Administration has granted approval to Rasonque, a drug from Revolution Medicines, for patients with advanced pancreatic cancer. The medicine, whose generic name is daraxonra…